Soft Tissue Sarcoma Market - Global Industry Size, Share, Trends Opportunity, and Forecast, 2020-2030F

The Soft Tissue Sarcoma Market was valued at USD 1.58 Billion in 2024, and is expected to reach USD 2.57 Billion by 2030, rising at a CAGR of 8.43%. Soft tissue sarcomas are primarily treated through surgical intervention, aiming to remove the tumor or affected tissue. Radiation therapy may be employed, either in conjunction with surgery or independently, to shrink or eliminate the tumor. Chemotherapy is frequently used as an adjunct to enhance the efficacy of other treatment options. The prognosis for soft tissue sarcomas varies significantly based on factors such as the type, location, and stage of the cancer. Generally, early diagnosis and prompt treatment lead to more favorable outcomes.

It is essential for healthcare providers to stay informed on the latest advancements in treatment, as therapies and prognoses continue to improve. Clinical trials are a vital avenue for accessing cutting-edge treatments and gaining valuable insights into optimal management strategies for soft tissue sarcomas. Participation in these trials can lead to better patient outcomes and an improved quality of life.

A comprehensive treatment approach combining surgery, radiation, and chemotherapy remains the cornerstone for managing soft tissue sarcomas. However, ongoing research is uncovering the potential of alternative therapies, including immunotherapy, targeted therapy, and even complementary treatments like herbal medicine. Additionally, lifestyle modifications such as dietary changes and regular exercise may reduce the risk of developing soft tissue sarcomas and contribute to the recovery process. These evolving treatment strategies, supported by clinical research, offer a more promising future for patients facing this condition.

Key Market Drivers

Increase in Cancer Cases

The increasing prevalence of cancer, including soft tissue sarcoma, significantly drives the growth of the global soft tissue sarcoma market. As the number of cancer diagnoses continues to rise globally, there is an expanding demand for advanced diagnostic tools, treatment options, and therapeutic solutions. The American Cancer Society projects that approximately 13,400 individuals, both adults and children, will be diagnosed with soft tissue sarcoma in 2023. Soft tissue sarcomas account for 1% of all adult cancers, 7% of cancers in children up to age 15, and 3% of cancers in children under the age of 14. Soft tissue sarcomas, though relatively rare, contribute to this trend, particularly as awareness of the disease improves and more individuals undergo diagnostic screenings. This growth in cancer cases is prompting healthcare providers, pharmaceutical companies, and research institutions to focus on the development of more effective and targeted therapies for soft tissue sarcoma.

The rising incidence of soft tissue sarcoma necessitates a broader range of medical interventions, from surgical procedures to radiation and chemotherapy treatments. As healthcare systems respond to this growing demand, there is a notable increase in investments for research and development, aiming to improve patient outcomes. Additionally, the advancement of personalized medicine and the growing interest in immunotherapies, targeted therapies, and combination treatments further accelerate market growth.

Furthermore, as the global healthcare landscape evolves, the market for soft tissue sarcoma treatments benefits from the ongoing shift toward more comprehensive and integrated treatment approaches. This includes the incorporation of next-generation therapies, the availability of novel drugs, and the expansion of clinical trials to test and refine new treatment modalities.

The increase in cancer cases also drives greater awareness and advocacy, which in turn promotes greater funding for cancer research, enhances the availability of state-of-the-art treatment options, and encourages the adoption of cutting-edge diagnostic technologies. The growing incidence of soft tissue sarcoma and the broader cancer landscape collectively fuel the demand for market solutions aimed at improving diagnosis, treatment, and patient care, ensuring continued growth in the soft tissue sarcoma market.

Development of New and Innovative Therapies

The development of new and innovative therapies is a key driver of growth in the global soft tissue sarcoma market. As medical research advances, the introduction of more effective, targeted, and personalized treatment options for soft tissue sarcoma significantly enhances patient outcomes and expands the market. These innovative therapies, including advancements in immunotherapy, targeted therapy, and combination treatments, are reshaping the treatment landscape for soft tissue sarcomas and fueling market expansion. One of the primary factors contributing to this growth is the increasing shift towards personalized medicine, which tailors treatments based on the individual characteristics of each patient's tumor.

This approach leads to more precise and effective therapies, reducing the risk of side effects and improving overall treatment efficacy. The growing understanding of the molecular and genetic underpinnings of soft tissue sarcomas has paved the way for the development of therapies that specifically target cancer cells, making treatments more efficient and minimizing damage to healthy tissues. The limited effectiveness of traditional treatment methods, including surgery, radiation, and chemotherapy, has driven significant research into novel immunotherapy options for soft tissue sarcoma (STS). Immune checkpoint inhibitors, such as anti-CTLA-4 and PD-1 therapies, have shown promising histologic-specific responses in the treatment of STS, offering new avenues for more targeted and effective therapies.

Additionally, immunotherapies, which leverage the body's immune system to fight cancer, have shown promising results in clinical trials. These therapies are gaining traction as alternative or adjunctive treatments to traditional methods such as surgery, radiation, and chemotherapy. The emergence of immune checkpoint inhibitors and other immune-based treatments has generated significant interest in the soft tissue sarcoma market, as they offer new hope for patients with advanced or metastatic disease.

Targeted therapies, designed to target specific molecules involved in cancer cell growth, are also driving market growth. These therapies can inhibit the progression of soft tissue sarcomas by interfering with the biological pathways that enable tumor growth and survival. As more targeted therapies are developed and approved, they provide an opportunity to improve survival rates and enhance the quality of life for patients with soft tissue sarcoma.

Moreover, the growing pipeline of clinical trials and the continued investment in research and development are fostering the discovery of novel therapeutic agents. Pharmaceutical companies, biotech firms, and research institutions are dedicating significant resources to developing cutting-edge treatments, which fuels competition and innovation in the market. The introduction of new therapies is not only expanding the treatment options available to clinicians but also attracting significant investment, thereby accelerating the overall market growth.

The development of new and innovative therapies is a critical factor driving the growth of the global soft tissue sarcoma market. The ongoing advancements in personalized medicine, immunotherapy, targeted therapies, and novel drug formulations are transforming the treatment landscape, improving patient outcomes, and expanding the market’s potential. These innovations are not only increasing the availability of more effective treatment options but also promoting further investment in research and development, contributing to the long-term growth and evolution of the market.

Rise In the Number of Product Approval for New Sarcoma Drugs

The rise in the number of product approvals for new sarcoma drugs is a significant factor driving the growth of the global soft tissue sarcoma (STS) market. As regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), continue to approve innovative therapies specifically designed for soft tissue sarcomas, the market for these drugs expands, offering new treatment options and improving clinical outcomes for patients. In 2020, the U.S. Food and Drug Administration (FDA) approved the first new anticancer therapeutics for the treatment of two distinct types of soft tissue sarcoma.

On January 9, 2020, the FDA granted approval for avapritinib (Ayvakit) to treat certain patients with gastrointestinal stromal tumors (GIST). On January 23, 2020, tazemetostat (Tazverik) was approved for the treatment of specific patients with epithelioid sarcoma. Soft tissue sarcomas are a rare and heterogeneous group of cancers that originate in the body's soft tissues, including muscles, tendons, fat, blood vessels, lymphatic vessels, nerves, and tissues surrounding joints. The World Health Organization recognizes over 50 different subtypes of soft tissue sarcoma, highlighting the complexity and diversity of these conditions.

The approval of new sarcoma drugs often leads to the diversification of treatment regimens, providing clinicians with more choices to address the complexities of soft tissue sarcomas. These newly approved drugs typically target specific molecular pathways or mechanisms involved in sarcoma growth, offering more precise and effective treatment options compared to traditional methods such as surgery, radiation, and chemotherapy. This shift toward targeted therapies allows for the development of drugs that are more effective in treating rare and complex sarcoma subtypes, thus meeting the unmet needs within the market.

In addition to improving treatment outcomes, the approval of new sarcoma drugs contributes to increased market competition. As more pharmaceutical companies enter the market with novel therapies, competition drives innovation and helps reduce treatment costs, ultimately making these advanced therapies more accessible to a broader patient population. Furthermore, this competitive landscape fosters further investment in research and development, accelerating the discovery of next-generation treatments and enhancing the overall growth of the market.

The approval of new drugs also stimulates greater awareness and adoption of advanced treatment options among healthcare providers and patients. This, in turn, leads to better diagnosis and improved access to cutting-edge therapies, resulting in a more favorable treatment landscape for soft tissue sarcoma. Additionally, the increasing availability of effective treatments encourages healthcare systems to allocate resources toward better sarcoma management, which further boosts market demand.

Moreover, regulatory agencies' accelerated approval pathways, such as the FDA’s orphan drug designation for rare cancers like soft tissue sarcoma, have facilitated the faster introduction of life-saving drugs. This trend has led to the introduction of breakthrough therapies that can significantly improve survival rates and quality of life for patients with advanced or metastatic soft tissue sarcomas.

In summary, the growing number of product approvals for new sarcoma drugs plays a pivotal role in the expansion of the global soft tissue sarcoma market. These approvals are driving innovation, enhancing treatment outcomes, increasing market competition, and improving patient access to novel therapies. The continuous flow of new, targeted drugs entering the market, coupled with regulatory incentives, fosters long-term market growth and presents new opportunities for both pharmaceutical companies and healthcare providers.

Key Market Challenges

High Cost of Treatments

High treatment costs can limit patient access to effective therapies, especially for individuals without adequate insurance coverage or financial resources. This can lead to delayed or suboptimal treatment, negatively impacting patient outcomes. The high out-of-pocket costs associated with STS treatments can place a significant financial burden on patients and their families, potentially leading to financial hardship and reduced quality of life.

High treatment costs can attract public and regulatory scrutiny, leading to pricing pressure and potential limitations on reimbursement and coverage. The substantial costs associated with treatment methods hinder market growth. Several treatments for this disease are expensive, posing challenges for individuals, particularly those in rural areas. Consequently, this becomes a significant obstacle for the market. The rising expenses of radiotherapy and chemotherapy might impede the growth of the soft tissue sarcoma treatment market in the forecast period.

Side-Effects of Soft Tissue Sarcoma Drugs

The presence of significant side effects associated with Soft Tissue Sarcoma (STS) drugs can hinder the growth of the STS market. Side effects can impact patient quality of life, influence treatment decisions, and contribute to challenges in patient adherence and acceptance of treatments. Severe side effects can lead to decreased patient quality of life, affecting their ability to perform daily activities, work, and engage in social interactions. This can discourage patients from pursuing or continuing treatment. Patients experiencing intolerable side effects might choose to discontinue treatment prematurely, potentially reducing the effectiveness of the therapy and hindering positive treatment outcomes. Elderly or frail patients might be more susceptible to side effects, limiting the use of certain drugs in this population and potentially reducing the market demand.

Key Market Trends

Introduction of Other Therapies

The availability of many therapies offers healthcare providers a broader range of options to tailor treatment plans based on the specific subtype, stage, and characteristics of each patient's STS. With a variety of therapies to choose from, physicians can personalize treatment approaches, optimizing the chance of positive responses and minimizing adverse effects. Different STS subtypes have varying responses to treatments. The introduction of multiple therapies can help address unmet medical needs for subtypes that lack effective treatment options. A multitude of therapies can lead to better patient outcomes, including increased survival rates, enhanced quality of life, and better management of disease-related symptoms.

The availability of many therapies encourages healthy market competition among pharmaceutical companies, leading to innovation, price competition, and improved treatment quality. For over four decades, the cornerstone of localized sarcoma treatment has involved surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after completing surgical resection, approximately 50.0% of patients with intermediate or high-grade sarcoma develop metastatic disease. The advent of targeted therapy has brought about a paradigm shift in the treatment approach for sarcoma. Targeted therapies and upcoming breakthroughs in the pipeline will continue to play a pivotal role in driving market growth throughout the forecast period.

Rising Healthcare Awareness

There is a growing awareness among patients and healthcare providers regarding the incidence of liposarcoma. Both patients and doctors are actively engaging in learning about the available therapies for treating these severe diseases, leading to increased market opportunities. Increased awareness prompts patients to seek medical attention at earlier stages of the disease, leading to timely diagnosis and treatment initiation. Early detection can result in better treatment outcomes and potentially higher survival rates.

Patients and healthcare providers who are more informed about available therapies can make more educated treatment decisions, leading to improved patient management and adherence to treatment plans. The increasing awareness about the incidence of liposarcoma among patients and healthcare providers creates a ripple effect that positively impacts diagnosis, treatment, research, advocacy, and market growth. As more attention is focused on this rare cancer, opportunities arise for collaboration, innovation, and improved patient care within the liposarcoma market.

Segmental Insights

Treatment Type Insights

The segment of anti-angiogenesis drugs is projected to experience rapid growth during the forecast period. This can be attributed to the growing demand for these drugs in cancer treatment. The prevalence of cancer and the necessity for effective therapies are driving factors behind this segment. Anti-angiogenesis drugs employ a molecular approach to hinder the formation of new blood vessels, which are essential for tumor growth and spread. This approach shows promise due to its relatively lower side effects compared to chemotherapy and radiation.

Furthermore, the advent of innovative cancer treatments like immunotherapy and gene therapy is expected to contribute to the expansion of the anti-angiogenesis drugs segment. As these treatments become more accessible, the demand for anti-angiogenesis drugs is anticipated to rise. Moreover, the increasing demand for personalized medicines is likely to create new opportunities for segment growth. However, the high cost of these treatments may impose limitations on the expansion of the anti-angiogenesis drugs segment.

End User Insights

Based on the end user segmentation, the market is categorized into hospitals, homecare, speciality centres, and others. The hospitals segment held the largest market share in 2024 and is projected to maintain its dominance throughout the forecast period. This can be attributed to increased government expenditure aimed at the development of the healthcare sector.

Regional Insights

The demand for soft tissue sarcomas in North America is projected to experience substantial growth during the forecast period. This can be attributed to the rising incidence of this cancer type in the region, coupled with the availability of advanced treatment options. Moreover, the increasing emphasis on research and development of innovative therapies, including immunotherapies and targeted therapies, is anticipated to propel the demand for soft tissue sarcomas in North America. Furthermore, the growing prevalence of personalized medicines and the presence of improved healthcare infrastructure in the region are expected to further drive the demand. However, it is important to note that the high cost of treatments may act as a limiting factor for the growth of this segment in the region.

Key Market Players

• F. Hoffmann-La Roche Ltd.
• Viatris Inc
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GSK plc
• Novartis AG
• Bayer AG
• Sun Pharmaceutical Industries Ltd.
• Merck & Co., Inc.

Report Scope:

In this report, the Global Soft Tissue Sarcoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Soft Tissue Sarcoma Market, By Treatment Type:

• Targeted Therapy
• Chemotherapy
• Anti-Angiogenesis Drugs
• Radiation Therapy
• Others

Soft Tissue Sarcoma Market, By End User:

• Hospitals
• Homecare
• Specialty Centres
• Others

Soft Tissue Sarcoma Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Soft Tissue Sarcoma Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.